

In the Specification:

Please amend the paragraph at page 1, lines 13-14 as follows:

The benefit of the May 30, 2000 filing date of provisional application 60/325,758 [60/nnn,nnn (which is a conversion of nonprovisional application 09/580,894)] is claimed under 35 U.S.C. § 119(e).

In the Claims:

Please amend Claims 10 and 13 as follows:

1 **10.** (once amended) A method as recited in Claim 1, wherein the matrix
2 comprises Matrigel™ matrix.

1 **13.** (once amended) A method as recited in Claim 1, additionally
2 comprising the step of supplying [an additional] a factor to the embedded tissue
3 sample, and measuring the difference in angiogenesis for the tissue sample as
4 compared to the angiogenesis of an otherwise identical and otherwise identically-
5 treated control tissue sample that is not supplied with the factor; whereby the
6 difference in observed angiogenesis is a measure of the angiogenic enhancement
7 or angiogenic suppression characteristics of the supplied factor.

REMARKS

The specification has been amended at page 1 to supply the serial number of the provisional application from which priority is claimed. At the time the present application was filed, that serial number was not yet available.

Claims 10 and 13 have been amended. The Claim amendments are intended as clarifications only, and are not intended to alter the scope of the Claims in any manner.

"Clean" versions of the amended Claims and of the amended portion of the specification appear in an Appendix.